Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hepatocellular Carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    367 result(s) found for: Hepatocellular Carcinoma. Displaying page 9 of 19.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2022-000998-31 Sponsor Protocol Number: APHP220267 Start Date*: 2023-03-10
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
    Full Title: Study of the benefit of lenvatinib treatment in waiting list of liver transplantation after TACE failure in patients with hepatocellular carcinoma (HCC) : Ta-Len-Tra.
    Medical condition: Patients with a non resectable HCC registered on national waiting list for LT with no complete response to TACE as a bridging loco-regional treatment.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004004-60 Sponsor Protocol Number: Rad-HCC Start Date*: 2017-03-02
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Prospective study of anti-inflammatory therapy post interventional radiological treatment of HCC in the cirrhotic patient.
    Medical condition: patients with HCC in the setting of cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10024662 Liver cell carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004126-13 Sponsor Protocol Number: CaPture Start Date*: 2020-10-06
    Sponsor Name:University Leipzig
    Full Title: Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 or PD-L1 inhibitors
    Medical condition: Hepatocellular carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004105-85 Sponsor Protocol Number: D910DC00001 Start Date*: 2019-09-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcin...
    Medical condition: Histologically or cytologically (or radiologically for patients undergoing curative ablation) confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (rese...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10077746 Hepatocellular carcinoma stage I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000051-16 Sponsor Protocol Number: JX594-HEP018 Start Date*: 2012-12-21
    Sponsor Name:Jennerex, Inc
    Full Title: A Phase 2b Randomized Open-Label Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma Wh...
    Medical condition: Advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000747-10 Sponsor Protocol Number: 2154/2006 Start Date*: 2006-07-21
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: PHASE II STUDY OF BAY 43-9006 AND INFUSIONAL 5-FLUOROURACIL IN ADVANCED HEPATOCELLULAR CARCINOMA
    Medical condition: patients with advanced inoperable hepatocellular carcinoma Child A or B
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019695 Hepatic neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003275-40 Sponsor Protocol Number: 63/2007/O/Sper Start Date*: 2008-07-29
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: New immunosuppressive treatments to reduce the rate of recurrence of hepatocellular carcinoma after liver transplantation
    Medical condition: Liver transplantation in patients with hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019695 Hepatic neoplasm LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004728-39 Sponsor Protocol Number: AURORA Start Date*: 2020-07-31
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to first line TreAtment
    Medical condition: Locally advanced or metastatic and/or unresectable HCC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005774-25 Sponsor Protocol Number: SC104 Start Date*: 2024-09-06
    Sponsor Name:SOTIO Biotech AG
    Full Title: A phase 2, open-label, single-arm, multicenter study of SOT101 in combination with pembrolizumab to evaluate the efficacy and safety in patients with selected advanced/refractory solid tumors
    Medical condition: advanced/refractory solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    24.1 100000004864 10085908 Cutaneous squamous cell carcinoma LLT
    21.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Temporarily Halted) CZ (Prematurely Ended) BE (Completed) IT (Prematurely Ended) HU (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002992-33 Sponsor Protocol Number: E7080-G000-304 Start Date*: 2013-07-04
    Sponsor Name:Eisai Limited
    Full Title: A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular...
    Medical condition: Unresectable Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002345-37 Sponsor Protocol Number: MK7902-012 Start Date*: 2020-03-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination wi...
    Medical condition: Incurable/Non-metastatic Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) NL (Completed) PT (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004096-21 Sponsor Protocol Number: CRAD001O2101 Start Date*: 2008-12-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase 1 open label/phase 2 randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma
    Medical condition: advanced hepatocellular carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003555-16 Sponsor Protocol Number: 21469 Start Date*: 2020-12-11
    Sponsor Name:BAYER AG
    Full Title: An Open-Label Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) after PD-1/PD-L1 Immune Checkpoint Inhibitors
    Medical condition: A type of liver cancer which may have spread to nearby tissue and is unlikely to be cured or controlled with treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000601-11 Sponsor Protocol Number: Soratace-1 Start Date*: 2008-03-06
    Sponsor Name:Medizinische Universität Wien Univ. Klinik f. Innere Med. III, Abt. f. Gastroenterologie/Hepatologie
    Full Title: SORATACE: Sorafenib (Nexavar®) as inhibitor of collateral tumor vessel growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a pilot trial to evaluate safety and ...
    Medical condition: hepatocellular carcinoma patients undergoing transarterial chemoembolisation (TACE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008852-18 Sponsor Protocol Number: PRAEMARKERAAT08 Start Date*: 2009-06-10
    Sponsor Name:Medizinische Universität Innsbruck Innere Medizin V
    Full Title: Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients
    Medical condition: The present project is an academic clinical trial in which patient suffering from hepatocellular carcinoma, non-small cell lung cancer, renal cell cancer and colorectal cancer treated routinely wit...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001401-42 Sponsor Protocol Number: Erlosora-1 Start Date*: 2008-12-03
    Sponsor Name:Medizinische Universität Wien, Univ. KlM III, Klinische Abt. f. Gastroenterologie/Hepatologie
    Full Title: Combination of Erlotonib plus Sorafenib in Patients with unresectable Hepatocellular Carcinoma; a randomized placebo controlled Phase II pilot trial.
    Medical condition: Unresectable Hepatocellular Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004505-34 Sponsor Protocol Number: 201800881 Start Date*: 2021-02-17
    Sponsor Name:University Medical Center Groningen
    Full Title: A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in patients with advanced untreatable hepatocellular carcinoma
    Medical condition: The anti-tumoral effect of cannabis oil will be investigated in patients with untreatable HCC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004566-26 Sponsor Protocol Number: 3152-301-002 Start Date*: 2017-06-19
    Sponsor Name:Tobira Therapeutics Inc., a subsidiary of Allergan plc
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholi...
    Medical condition: Liver fibrosis in Subjects with Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Prematurely Ended) AT (Completed) ES (Prematurely Ended) HU (Completed) GB (GB - no longer in EU/EEA) PL (Completed) SI (Completed) GR (Completed) LV (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-002326-75 Sponsor Protocol Number: 8-55-58102-004 Start Date*: 2012-09-27
    Sponsor Name:Ipsen Pharma
    Full Title: A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas.
    Medical condition: advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas in patients who have progressed after standard therapies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000123-26 Sponsor Protocol Number: PRODIGE 10/VA 2007-40 Start Date*: 2008-07-31
    Sponsor Name:Centre Val d'Aurelle Paul Lamarque
    Full Title: Etude de phase II, randomisée, testant l'association Nexavar (sorafenib) gemcitabine et oxaliplatine (GEMOX) dans le traitement des carcinomes hépatocellulaires non accessibles à un traitement chir...
    Medical condition: Carcinome hépatocellulaire non accessible à une chirurgie ou à une destruction per-cutanée.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 02:48:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA